RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo trial targets stubborn blood cancer
Disease control Recruiting nowThis study is testing whether adding an immunotherapy drug (obinutuzumab) earlier to a two-drug combination (acalabrutinib + venetoclax) works better for people with chronic lymphocytic leukemia (CLL) that has returned or hasn't responded to previous treatments. The goal is to be…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug duo aims to wipe out stubborn blood cancer cells
Disease control Recruiting nowThis study is testing whether combining two targeted drugs, acalabrutinib and venetoclax, can better control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to prior treatment. It will involve about 20 adults who hav…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New Triple-Target immune therapy enters human trials for aggressive blood cancers
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of a new type of CAR-T cell therapy designed to attack three different proteins (CD19, CD20, and CD22) found on cancer cells. It is for adults with certain aggressive blood cancers like non-Hodgkin lymphoma, acute lymphob…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New drug trial targets Tough-to-Treat blood cancer after other treatments fail
Disease control Recruiting nowThis study is testing an oral drug called mirdametinib for adults with chronic lymphocytic leukemia (CLL) or a related lymphoma that has returned or stopped responding to standard treatments. The drug aims to block a specific signal that tells cancer cells to grow, potentially sl…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New engineered immune cell therapy enters first human trials for aggressive blood cancers
Disease control Recruiting nowThis is an early-stage study testing a new type of personalized cell therapy called MC10029 for adults with B-cell blood cancers that have come back or stopped responding to standard treatments. Researchers will first find the safest dose and then see if the therapy can shrink tu…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
Faster drug Ramp-Up tested for tough blood cancers
Disease control Recruiting nowThis study is testing if a faster, higher dose increase of a new drug called sonrotoclax is safe and tolerable for patients with certain blood cancers. It is for adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL), inclu…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New pill aims to turn immune system against tough blood cancers
Disease control Recruiting nowThis early-stage study is testing a new oral medication called Q702 for patients with advanced blood cancers and rare immune cell disorders that have not responded to standard treatments. The main goals are to find the safest dose and see what side effects occur. Researchers hope…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC